Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China. Show more
Location: Suzhou Industrial Park, Suzhou, 215000, China | Website: https://www.ascentage.cn | Industry: Biotechnology | Sector: Healthcare
Market Cap
3.84B
52 Wk Range
$16.50 - $48.45
Previous Close
$41.31
Open
$39.00
Volume
12,209
Day Range
$38.61 - $39.58
Enterprise Value
3.844B
Cash
1.661B
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.09%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lisaftoclax (APG-2575) + azacitidine (AZA) Details Treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies | Phase 3 Initiation | |
Olverembatinib Details Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) | Phase 2 Update | |
Alrizomadlin (APG-115) +/- toripalimab Details Advanced adenoid cystic carcinoma (ACC) | Phase 2 Update |